Blueprint Medicines Corpo... (BPMC)
92.07
-1.87 (-1.99%)
At close: Feb 18, 2025, 3:59 PM
92.48
0.45%
After-hours: Feb 18, 2025, 04:42 PM EST
undefined% (undefined)
| Bid | 92 |
| Market Cap | 5.88B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -86.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 93.6 |
| Volume | 994,535 |
| Avg. Volume (20D) | 833,384 |
| Open | 94.31 |
| Previous Close | 93.94 |
| Day's Range | 91.61 - 95.10 |
| 52-Week Range | 80.42 - 121.90 |
| Beta | undefined |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 30, 2015
Employees 649
Stock Exchange NASDAQ
Ticker Symbol BPMC
Analyst Forecast
According to 18 analyst ratings, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $125, which is an increase of 35.77% from the latest price.
Buy 66.67%
Hold 27.78%
Sell 5.56%
Next Earnings Release
Blueprint Medicines Corporation is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
-8.08%
Blueprint Medicines shares are trading lower after...
Unlock content with
Pro Subscription
1 month ago
+18.22%
Blueprint Medicines shares are trading higher after the company reported a year-over-year increase in FY24 AYVAKIT revenue results.
1 month ago · https://thefly.com
Blueprint Medicines price target lowered by $11 at Wedbush, here's whyBlueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%)
